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Thirty-eight patients with organic heart disease and his•
tory of sudden cardiac arrest or recurrent sustained ven•
tricular tachycardia were treated with flecainide. Coro•
nary artery disease was present in 33 patients. Previous 
antiarrhythmic therapy consisted of two to eight drugs 
(mean four). Fourteen patients were resuscitated from 
sudden cardiac death and 24 patients had chronic re•
current sustained ventricular tachycardia. Twenty-eight 
patients had electrophysiologic testing before and during 
flecainide treatment. Sustained ventricular tachycardia 
became noninducible in 5 patients, nonsustained in 5 
patients and slowed in 13 patients (cycle length increased 
from 278 ± 64 to 395 ± 91 ms; p = 0.002). Three of 
the 14 patients with sudden cardiac death and 15 of the 
24 patients with recurrent sustained ventricular tachy•
cardia remained on long-term flecainide treatment. The 
Flecainide acetate is a new antiarrhythmic agent belonging 
to a unique series of trifluoroethoxybenzamides. Classified 
as a sodium channel blocking agent, flecainide is reported 
to have several times the potency of procainamide, quinidine 
and lidocaine. Because of its potent negative dromotropic 
effect without marked increase in duration of repolarization, 
it has been subclassified as a type IC agent (1). Flecainide 
has been used in the treatment of ventricular and supraven•
tricular arrhythmias (2-5). Its ability to suppress ventricular 
premature complexes has been reported (2). However, there 
are few reports of its use in the treatment of patients suffering 
from recurrent, sustained ventricular tachycardia and pa•
tients resuscitated from sudden cardiac death. We report 
here the experience of three centers where flecainide was 
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mean left ventricular ejection fraction in 16 of these 18 
patients was 37%. Nonlimiting side effects occurred in 
seven patients (18%). Proarrhythmic effects were seen 
in four patients (10%). 
At a mean follow-up time of 11 ± 3 months, 15 
patients (39%) had had no recurrence, including 5 who 
had inducible sustained ventricular tachycardia and 5 
who did not on retesting during treatment. In the 18 
patients who received long-term therapy, 3 late deaths 
occurred, 1 of which was of arrhythmic origin. These 
data suggest that flecainide is effective in about 40% of 
patients with severe refractory ventricular arrhythmias. 
Its value as a single drug in the treatment of sudden 
cardiac death remains to be defined. 
(J Am Coil CardioI1985;6:772-9) 
given to 38 patients who suffered from recurrent sustained 
ventricular tachycardia or who had been resuscitated from 
out-of-hospital cardiac arrest. 
Methods 
Patient selection. The study was conducted from Jan•
uary 1982 through March 1984 at the Jewish Hospital at 
Washington University in St. Louis, the Medical College 
of Wisconsin Hospitals in Milwaukee and the Hermann 
Hospital at the University of Texas Medical School in Hous•
ton. Participants were men and women, 16 years of age and 
older, with electrocardiographically documented chronic, 
recurrent, sustained ventricular tachycardia usually associ•
ated with clinically apparent organic heart disease, or who 
had been resuscitated from sudden cardiac death. Exclusion 
factors were: left ventricular ejection fraction less than 15%; 
first degree atrioventricular (A V) block beyond 0.28 second; 
second and higher degree A V block; current treatment with 
calcium channel blocking agents; creatinine clearance less 
than 20 mllmin; digitalis intoxication; artificial ventricular 
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pacing and pregnancy or child-bearing potential. Efforts 
were made to avoid the concomitant use by the study par•
ticipants of other antiarrhythmic drugs. 
Sudden cardiac death was defined as slldden circulatory 
collapse, without associated myocardial infarction, resulting 
in a loss of consciousness and vital signs and requiring 
cardiopulmonary resuscitation, including direct current shock. 
Sustained ventricular tachycardia was defined as ventricular 
tachycardia at a rate greater than 120/min, lasting longer 
than 30 seconds or requiring immediate termination because 
of hemodynamic instability. During electrophysiologic test•
ing, nonsustained ventricular tachycardia was defined as six 
or more consecutive self-terminating ventricular beats oc•
curring at a rate of 120 beats/min or faster. 
Proarrhythmic effect of the drug was defined as the oc•
currence of a new tachyarrhythmia not previously docu•
mented; a marked increase in rate of ventricular tachycardia; 
a change in type of ventricular tachycardia, such as non•
sustained to sustained during electrophysiologic studies; or 
the new development, during treatment, of torsade de pointes 
or ventricular fibrillation. When the baseline frequency of 
ventricular premature complexes was 1 to 50 per hour, a 
10-fold increase in frequency of ventricular premature com•
plexes was considered to be a proarrhythmic effect. When 
the baseline frequency of ventricular premature complexes 
was higher, a fivefold increase was defined as proarrhythmic. 
Clinical characteristics (Table 1). Thirty men and eight 
women, 16 to 75 years old (mean, 57.3 year~), were enrolled 
in the study. Fourteen patients (Group I) had been resus•
citated from sudden cardiac death, and 24 (Group II) had 
chronic recurrent sustained ventricular tachycardia. Thirty•
three patients suffered from coronary artery disease, two 
from mitral valve pro~apse, two from hypertensive cardio•
myopathy and one from congestive cardiomyopathy. All 
patients had failed to respond to previous antiarrhythmic 
drugs or were intolerant of these drugs. Previous unsuc•
cessful antiarrhythmic therapy included administration of 
a mean of four conventional or investigational drugs (range 
two to eight per patient). Measurement of left ventricular 
Table 1. Clinical Characteristics of 38 Patients 
No. of Patients M/F 
Clinical presentation 
Sudden cardiac death (Group J) 
Sustained ventricular tachycardia 
(Group II) 
Total 
Diagnosis 
Coronary artery disease 
Mitral valve prolapse 
Hypertensive cardiomyopathy 
Congestive cardiomyopathy 
Total 
F = female patients; M = male patients. 
14 
24 
38 
33 
2 
2 
38 
1113 
19/5 
30/8 
28/5 
III 
012 
110 
30/8 
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ejection fraction was obtained in 35 patients and ranged 
from 15 to 75% (mean 46). No patient was treated for a 
tachyarrhythmia occurring only during exercise or emotional 
stress. 
Study protocol. All patients were admitted to a telem•
etry unit and the cardiac rhythm was continuously monitored 
during the entire hospital phase of the trial. After granting 
their informed consent, the patients underwent a pretreat•
ment evaluation during which all antiarrhythmic drugs were 
discontinued. The pretreatment evaluation was based on the 
patient's history, physical examination, 12 lead electrocar•
diogram, chest X-ray film, ophthalmologic examination and 
assessment of left ventricular function by radionuclide or 
contrast angiogram. In 16 patients, 24 hour electrocardio•
graphic recordings were made before and during treatment 
for precise quantitative measurements of spontaneous ven•
tricular ectopic activity. Thirty-two patients underwent pre•
treatment electrophysiologic testing, and in six patients who 
had frequently recurrent sustained ventricular tachycardia, 
treatment was guided by continuous electrocardiographic 
monitoring. In 28 patients with sporadic symptomatic sus•
tained ventricular tachycardia or sudden cardiac death, 
electrophysiologic testing was performed before and during 
drug administration. 
In all patients the clearance period for a previously given 
antiarrhythmic agent was at least five drug half-lives in 
duration. Three patients received flecainide, 2 mg/kg, over 
20 minutes intravenously during the baseline electrophysi•
ologic study. One of these patients (Case 9), who had no 
apparent benefit from the drug given intravenously, was not 
offered oral therapy. All other patients were placed on oral 
treatment, starting at a dose of 100 mg every 12 hours. If 
this was well'tolerated, the dose was increased by increments 
of 100 mg/day every 2 to 4 days. In the first 12 patients, 
the maximal daily dose administered was limited to 600 mg. 
In the last 26 trials, this limit was decreased by the sponsor 
of the drug to 400 mg because of pro arrhythmic compli•
cations occurring with higher doses. Ultimately, no patient 
w'as discharged from the hospital on a dose higher than 400 
mg/day, and no patient in this series manifested proar•
rhythmic complications while receiving more than 400 
mg/day. 
A 12 lead electrocardiogram was recorded before each 
increase in dosage. All electrocardiographic measurements 
were made from tracings recorded at 25 mm/s, using cali•
pers, and were confirmed by one of the investigators. In 24 
patients, blood samples were drawn before each increase in 
dosage for trough level determination. In the hospital, the 
results of treatment were measured by continuous telemetry 
monitoring, by analysis of 24 hour electrocardiographic re•
cordings made before discharge from the hospital, and, in 
patients whose tachyarrhythmia had been induced in the 
laboratory, by electrophysiologic testing during steady state 
administration of the highest tolerated dose of flecainide. 
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Follow-up. Patients discharged from the hospital on a 
drug regimen including flecainide were seen in the arrhyth•
mia clinic at regular intervals for long-term monitoring of 
drug safety and efficacy and verification of compliance. 
Efficacy was verified by patient questioning and by repeating 
24 hour ambulatory electrocardiographic recordings at 1 
month and subsequent 3 month intervals after hospital dis•
charge. At each visit, a 12 lead electrocardiogram and he•
matologic and biochemical profiles were obtained. Follow•
up radionuclide angiograms were ordered for patients in 
New York Heart Association functional class III or class 
IV or patients with cardiomegaly on chest X-ray film before 
flecainide therapy. All tapes from 24 hour ambulatory elec•
trocardiograms were analyzed by a central commercial com•
puterized facility (Cardio-Data). All plasma flecainide level 
determinations were performed in S. F. Chang's laboratory 
(Riker Inc.) by a gas-liquid chromatographic method de•
scribed in detail elsewhere (6-8). 
Electropbysiologic testing. Electrophysiologic studies 
were performed with the patient in the nonsedated, postab•
sorptive state. Electrode catheters were placed in the high 
right atrium, in the region of the bundle of His and at the 
right ventricular apex. The arterial pressure was continu•
ously monitored from the femoral artery. Three surface 
electrocardiographic leads were recorded together with in•
tracardiac electrograms from the right atrium, bundle of His 
and right ventricle. All signals were processed, displayed 
and recorded by an Electronics for Medicine VR-16 am•
plifying and recordjng system. Programmed stimulation was 
performed using Bloom DTU-101 or Medtronic 2332 or 
5325 stimulators with 1.8 to 2 ms impulses delivered at 
twice diastolic threshold. The stimulation protocol included 
rapid atrial pacing from a cycle length of 600 ms to Wencke•
bach A V conduction; single and double atrial extrasti•
mulation during sinus rhythm and during atrial paced rhythm 
at cycle lengths of 600, 500 and 400 ms; single and double 
ventricular extrastimulation during sinus rhythm and during 
ventricular paced rhythm at cycle lengths of 600, 500 and 
400 ms; rapid ventricular pacing from a cycle length of 600 
to 300 ms; and ventricular burst pacing from a cycle length 
of 290 ms to maximal 1: 1 ventricular capture. If this failed 
to induce ventricular tachycardia, triple ventricular extra•
stimulation was performed during sinus rhythm and ventric•
ular paced rhythm at cycle lengths of 600,500 and 400 ms. 
If ventricular tachycardia was noninducible from the right 
ventricular apex, stimulation of the septum at the right ven•
tricular outflow tract was performed. As long as no arrhyth•
mia was induced, stimulation was continued to the end of 
the protocol, including triple extrastimulation. The decision 
to advance further into the protocol when reproducible runs 
of nonsustained ventricular tachycardia were induced was 
left to the discretion of the investigator. Thus, in some 
instances when the investigator anticipated that further pro•
grammed stimulation would result in a sustained rhythm 
lACC Vol. 6. No.4 
October 1985:772-9 
requiring cardioversion, reproducible non sustained ventric•
ular tachycardia was used as the end point to treat. 
Criteria for entry into long-term treatment. LOflg•
term treatment was offered when all of the following were 
achieved: 1) Elimination of all episodes of spontaneous ven•
tricular tachycardia during in-hospital monitoring; 2) At least 
80% measured reduction in premature ventricular com•
plexes; 3) Elimination of sustained tachyarrhythmia during 
follow-up electrophysiologic study, or transformation into 
a nonsustained rhythm or to a sustained rhythm slowed to 
such a degree that it had become hemodynamically stable. 
Alternatively, if nonsustained ventricular tachycardia was 
induced during baseline electrophysiologic study, long-term 
treatment was considered only if ventricular tachycardia was 
not inducible during the follow-up procedure; and 4) Good 
subjective tolerance of the drug in doses found effective 
according to t\1e foregoing criteria. 
Data analysis. Pooled numerical results are indicated as 
mean ± standard deviation (SD). Statistical differences were 
determined by paired t test. 
Results 
In-hospital trial (Fig. 1). Group I (14 patients resus•
citated from sudden cardiac death). Among these 14 pa•
tients, flecainide treatment was discontinued in 9 because 
of insufficient antiarrhythmic protection, in 1 because of 
pro arrhythmic effect and in 1 because of implantation of an 
automatic defibrillator. One patient had noncardiac adverse 
effects. Three patients completed the in-hospital phase of 
the trial and remained on long-term flecainide therapy. One 
of them required the addition of amioc/arone because of 
persistent inducible sustained ventricular tachycardia during 
electrophysiologic testing. He was discharged from the hos•
pital on a daily regimen of 200 mg of flecainide and 400 
Figure 1. Results of ftecainide therapy in Group I (14 patients 
resuscitated from sudden cardiac death [SeD]) and Group II (24 
patients with sustained ventricular tachycardia [VTS]). EPS = 
electrophysiologic study. 
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mg of amiodarone. The other two patients were discharged 
from the hospital on a daily regimen of, respectively, 300 
and 400 mg of flecainide. The trough flecainide level for 
the group was 636 ± 25 ng/ml. 
the trial. One patient who remained on long-term therapy 
required the addition of amiodarone, 400 mg daily, and 
mexiletine, 600 mg daily, because of persistent inducible 
sustained ventricular tachycardia; addition of these drugs 
resulted in further slowing of the rate of the tachycardia. In 
this group the mean effective daily dose of drug in patients 
discharged on flecainide therapy was 293 ± 17 mg; the 
predischarge trough plasma level, measured in 14 patients, 
was 655 ± 25 ng/ml. Note that four patients from this 
group were discharged from the hospital on long-term ther•
apy with flecainide guided by the elimination of frequently 
occurring sustained ventricular tachycardia during contin•
uous electrocardiographic monitoring. 
Group II (24 patients treated for re(:urrent sustained 
ventricular tachycardia). Flecainide treatment was discon•
tinued in five patients because of insufficient antiarrhythmic 
protection during electrophysiologic testing and because of 
spontaneous recurrences noted on telemetry monitoring in 
three patients. A proarrhythmic effect was seen in one pa•
tient, but there were no noncardiac adverse effects requiring 
discontinuation of the medication. Adverse effects such as 
visual blurring, anorexia, headache and weakness, usually 
subsiding with adjustment of dosage, were noted in five 
patients. Fifteen patients completed the in-hospital phase of 
Observations during electrophysiologic studies (Table 
2 and Fig. 2). Thirty-two patients underwent electrophys-
Table 2. Results of Electrophysiologic Studies on 28 Patients Before and During Flecainide Treatment 
Baseline 
Method 
Clinical Induced of 
Case Presentation Rhythm Induction CL of VT 
I 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
18 
19 
21 
22 
23 
24 
25 
27 
28 
29 
30 
31 
33 
34 
35 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
SCD 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTS 
VTNS 
VTS 
VTS 
VTNS 
VTS 
VTS 
VTS 
SI,2,3,4 
SI,2,3 
DNA 
SI,2,3 
V-burst 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3,4 
SI,2,3 
SI,2,3 
VTNS SI,2,3 
VTNS SI,2,3,4 
VTS SI,2,3 
VTS SI,2,3 
VTS SI,2,3 
VTS RVP 
VTS SI,2 
VTS SI,2,3 
VTS SI,2,3 
VTNS SI,2,3 
VTS 
VTNS 
VTNS 
VTS 
VF 
VTS 
VTS 
V-burst 
SI,2,3,4 
SI,2,3 
SI,2,3 
SI,2,3,4 
SI,2,3 
SI,2,3 
260 
270 
300 
265 
300 
290 
225 
210 
220 
210 
160 
255 
215 
400 
210 
400 
300 
300 
230 
270 
300 
220 
270 
220 
240 
230 
280 
261 ± 16* 
On Flecainide 
Flecainide Plasma 
Dose Level Induced Method of 
(mg/day) (ng/ml) Rhythm Induction 
300 
400 
200 
200 
300 
300 
400 
134iv 
300 
100 
400 
400 
200 
200 
300 
300 
300 
300 
400 
300 
400 
400 
200 
300 
300 
300 
300 
300 
VTS 
VTS 
VTNS 
VTS 
512 VTS 
VTNS 
450 VTS 
254s VTS 
743 VTNS 
507 VTS 
569 NI 
898s 
676s VTNS 
266 VTNS 
566 VTS 
622 VTS 
VTS 
741s NI 
VTNS 
VTNS 
236 NI 
966 VTS 
NI 
208 
501 
810 
796 
673 
1,057s 
VTNS 
VTNS 
NI 
VTS 
VTS 
784 VTS 
S I ,2,3,4 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3,4 
SI,2,3 
SI,2 
SI,2,3,4 
SI,2,3 
RAP & RVP 
SI,2,3,4 
V-burst 
SI,2,3 
SI,2,3 
SI,2,3 
SI,2,3 
V-burst 
SI,2,3,4 
SI,2 
Discharged 
CL of VT on Flecainide 
350 
300 
440 
330 
365 
360 
340 
240 
260 
380 
250 
270 
580 
375 
445 
270 
380 
370 
300 
310 
600 
400 
540 
368 ± 19* 
Yes 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
No 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Additional 
Treatment 
AID 
Amiodarone 
Amiodarone & 
mexiletine 
Propranolol 
Metoprolol 
Timolol 
*Values calculated for paired data only. AID = automatic implantable defibrillator; CL = cycle length (ms); DNA = data not available; iv = 
intravenously; NI = noninducible; RAP = rapid atrial pacing; RVP = rapid ventricular pacing; s = level obtained during electrophysiologic study; 
SCD = sudden cardiac death; SI,2 = single extrastimulation; SI,2,3 = double extrastimulation; SI,2,3,4 = triple extrastimulation; V-burst = 
ventricular burst pacing; VF = ventricular fibrillation; VT = ventricular tachycardia; VTNS = nonsustained ventricular tachycardia; VTS = sustained 
ventricular tachycardia. 
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Figure 2. Observations during electrophysiologic studies (EPS) 
and long-term outcqrne. VF = ventricular fibrillation; VTNS = 
nonsustained ventricular tachycardia; other abbreviations as in Fig•
ure I. 
iologic testing before treatment. Twenty-nine of these pa•
tients were studied while receiving flecainide, one of whom 
had not undergone electrophysiologic testing before treat•
ment. Four patients did not undergo repeat electrophysio•
logic testing during treatment because of recurrence of spon•
taneous ventricular tachycardia. The AH and HV intervals 
were measured at similar cycle lengths in the control study 
and in the study with flecainide in 13 patients. The AH 
interval increased after flecainide administration from 85 ± 
9 to 107 ± 10 ms (p = 0.0(01). Flecainide also increased 
the HV interval from 53 ± 7 to 67 ± 8 ms (p = 0.015). 
Ventricular effective refractory period was measured during 
both studies at similar pacing cycle lengths from identical 
right ventricular sites in 22 patients. It was longer after 
JACC VoL 6. No.4 
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flecainide in 19 patients, unchanged in 1 and shorter in 2 
patients. The mean ventricular effective refractory period 
for the group during paced rhythm increased from 245 ± 
16 to 277 ± 17 ms (p = 0.0001). Before treatment, sus•
tained ventricular tachycardia was induced in 22 patients, 
nonsustained ventricular tachycardia in 9 and ventricular 
fibrillation was induced in 1. 
At follow-up testing during oral jiecainide treatment, 
ventricular tachycardia was noninducib1e in five patients and 
sustained ventricular tachycardia became nonsustained in 
five. Ventricular tachycardia cycle length increased from 
278 ± 64 to 395 ± 91 ms (p = 0.002) in 13 patients; 
ventricular tachycardia cycle length decreased from 318 to 
280 ms in 2 and non sustained ventricular tachycardia be•
came sustained in 3, although the rate of the induced tachy•
cardia was slower (mean cycle length increased from 266 
to 326 ms). 
Electrocardiographic changes (Table 3). With respect 
to the 12 lead electrocardiogram, flecainide produced a sta•
tistically significant increase in PR interval (p = 0.005) and 
QRS duration (p = 0.000l), but no significant change in 
sinus rate or corrected QT interval. 
Effect on ventricular premature activity in 24 hour 
electrocardiographic recordings (Table 4). Analysis of 
baseline and predischarge 24 hour ambulatory electrocar•
diograms was performed in 16 patients. For this analysis, 
ventricular tachycardia was defined as three or more con•
secutive ventricular beats. Ventricular tachycardia was to•
tally suppressed on the second recording in six patients and 
decreased by more than 80% in two patients. Eight patients 
had no episodes of ventricular tachycardia on either re•
cording. Ten patients had greater than 95% suppression of 
premature ventricular complexes on the second recording 
and three had greater than 80% suppression. Two patients 
had no premature ventricular complexes on either recording. 
One patient had a single ventricular premature complex on 
both recordings. 
Cardiac and noncardiac adverse effects (Table 5). 
Flecainide had a proarrhythmic effect in 4 of the 38 patients 
treated. In one patient (from Group I), widening of the QRS 
complex was noted on the electrocardiogram after a single 
oral dose of 200 mg, and spontaneous ventricular tachy•
cardia followed by fibrillation occurred. This was success•
fully treated with direct current shock and intravenous lid•
ocaine administration. Another patient had several episodes 
of spontaneous ventricular tachycardia (rate 110 beats/min) 
Table 3. Electrocardiographic Changes in 38 Patients 
Rate (per min) 
PR interval (s) 
QRS duration (s) 
QTc interval (s) 
Before Flecainide 
75 ± 9 
0.18 ± 0.42 
0.10 ± 0.31 
0.45 ± 0.67 
On Flecainide 
72 ± 9 
0.21 ± 0.42 
0.12 ± 0.34 
0.44 ± 0.66 
p Value 
NS 
0.005 
0.0001 
NS 
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Table 4. Results of 24 Hour Ambulatory Electrocardiogram 
Before Flecainide 
Case Total VPCs Couplets Runs* Total VPC 
8 4,932 224 0 20 
II 10,850 1,220 690 13 
17 25,961 Frequent Frequent 245 
18 5,814 936 614 748 
19 19 2 0 0 
20 12,913 126 8,412 159 
21 195 6 0 6 
22 I 0 0 
28 12,908 1,333 815 43 
29 7,096 132 0 222 
30 6,476 306 9 191 
31 0 0 0 5 
33 21,509 226 45 4,758 
34 293 6 0 3 
35 23,089 2,628 3,300 3,965 
36 262 76 0 90 
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On Flecainide 
Dose/Day Plasma Level 
Couplets Runs* (mg) (ng/ml) 
0 0 200 378 
0 0 100 462 
0 0 300 708 
0 86 200 566 
0 0 300 622 
6 0 300 706 
0 0 200 706 
0 0 300 606 
0 0 400 
12 0 200 208 
0 0 300 657 
0 0 300 810 
274 9 200 619 
0 0 300 673 
86 0 300 731 
0 0 300 909 
*Runs are three or more consecutive ventricular beats. VPCs = ventricular premature complexes. 
that were hemodynamically well tolerated. Two other pa•
tients developed an incessant slow ventricular rhythm at a 
rate of 92 and 90 beats/min, respectively. These three pa•
tients from Group II were considered to have experienced 
proarrhythmic effects either because there was a distinct 
increase in the frequency of the ventricular rhythm, albeit 
at slow rates, or because the arrhythmia changed from spo•
radic to incessant. 
In one patient heart failure worsened after administration 
of ftecainide. This patient had undergone surgical plication 
of a left ventricular aneurysm and was receiving digoxin 
therapy. He developed signs and symptoms of overt left 
ventricular failure several weeks after initiation of ftecainide 
treatment, and his left ventricular ejection fraction had de•
creased from 37 to 26%. Signs and symptoms of congestive 
heart failure resolved after addition of furosemide and cap-
Table 5. Adverse Effects 
Adverse Effect No. of Patients* 
Proarrhythmic 4 
Visual blurring 2 
Headache 2 
Weakness 3 
Nausea 2 
Anorexia 2 
Vertigo 
Congestive failure 
Rate-related BBB 
Treatment 
Discontinued 
Yes No 
4 0 
0 2 
0 2 
0 3 
0 2 
0 2 
0 
0 
0 
*Same patient may have more than one side effect. BBB = bundle 
branch block. 
topril to the drug regimen. One patient developed rate•
related left bundle branch block after initiation of therapy. 
Six patients experienced noncardiac adverse effects, the 
most common of which was weakness (three patients). Two 
patients had headache, anorexia, nausea and visual blurring. 
These symptoms were self-limited and usually responded 
to adjustment in dosage. 
Long-term treatment and follow-up (Table 6). Eighteen 
patients (48%) remained on long-term ftecainide treatment. 
During a period ranging from 2 to 21 months (mean, 11 ± 
3 months), 15 patients have been free of clinical recurrences 
of ventricular tachycardia. Of these 15 patients, 2 were from 
Group I and 13 from Group II. Left ventricular ejection 
fraction in the two Group I patients was 30 and 55%, re•
spectively; in the 13 patients from Group II left ventricular 
ejection fraction ranged from 15 to 75% (mean, 38%). Three 
patients were discharged on treatment with beta-receptor 
blocking drugs as secondary prevention after myocardial 
infarction or because exercise or emotional stress appeared 
to contribute to their ventricular electrical instability. 
Three patients died during the follow-up period. One 
patient had been discharged from the hospital on a regimen 
of ftecainide combined with mexiletine and amiodarone, the 
only drug combination that eliminated spontaneous recur•
rences of hypotensive ventricular tachycardia during hos•
pitalization. This patient died suddenly 2 months after dis•
charge. Another patient died from acute myocardial infarction 
after 6 months of treatment. The third patient, who had end•
stage cardiomyopathy, died from heart failure. On ftecainide 
treatment alone, he had symptomatic recurrences of ven•
tricular tachycardia requiring automatic internal cardiover•
sion. Amiodarone, previously ineffective as a single agent, 
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Table 6. Long-Tenn Follow-Up* 
No. Discharged Mean 
Group Enrolled on Flecainide LVEF 
14 3 33 ± 5 (n = 3) 
II 24 15 38 ± 6 (n = 13) 
Symptomatic Side Dose 
Recurrence Effects Adjusted 
0 0 
6 2 
Death 
Sudden Nonsudden 
0 
2t 0 
lACC Vol. 6, No.4 
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*Follow-up of 2 to 21 months (11 ± 3); tone death from acute myocardial infarction. LVEF = left 
ventricular ejection fraction. 
was added to ftecainide with control of ventricular tachy•
cardia for 14 months. 
Discussion 
Several drugs have recently been developed to fill the 
obvious need for additional safe and effective antiarrhythmic 
agents. Flecainide, one such agent, appears promising. It 
has favorable pharmacokinetic properties and the ease of 
twice a day dosage. One double-blind, multicenter study 
(4) reported ftecainide to be significantly more effective than 
quinidine in eliminating premature ventricular activity as 
well as complex or repetitive ventricular ectopic activity. 
However, to date only a few studies (9-12) have investi•
gated the safety and efficacy of ftecainide in high risk pa•
tients with life-threatening ventricular arrhythmias. 
Efficacy of ftecainide therapy. Our results indicate that 
ftecainide may suppress ventricular tachycardia on a long•
term basis in as many as 39% of patients with severe ar•
rhythmias. This rate compares favorably with the reported 
efficacy of other antiarrhythmic drugs in similar patient groups 
(13). Anderson (11) reported a higher long-term success 
rate with ftecainide in a small group of patients with sus•
tained ventricular tachycardia or syncope with ventricular 
arrhythmia. The major difference between this group of 
patients and ours is the lower mean left ventricular ejection 
fraction in our patients. Anderson reported a higher percent 
of total suppression of ventricular tachycardia on electro•
physiologic testing after oral ftecainide administration. Of 
his nine patients whose arrhythmia was totally suppressed, 
seven had a left ventricular ejection fraction greater than 
50% and were in functional class I or II. In our series, three 
of the five patients whose tachycardia was noninducible on 
follow-up study had severe left ventricular dysfunction. 
Reid et al. (10) reported their experience with ftecainide 
in a similar group of patients; 89% of them had complete 
elimination of ventricular tachycardia on ambulatory 
electrocardiographic monitoring. Flecainide was discontin•
ued in 5.5% because of noncardiac side effects and in 13% 
because of cardiac adverse effects and proarrhythmic ef•
fects. These investigators reported a 16% mortality rate due 
to recurrence of ventricular tachycardia during the follow•
up period and an 11 % mortality rate from other causes 
during a follow-up period of 101 days. The unusual aspect 
of their study is that in several cases of ventricular tachy•
cardia recurring after ftecainide therapy was initiated, suc•
cessful cardioversion to a normal rhythm could not be ac•
complished. We did not encounter this problem. The lower 
doses administered to our patients compared with the doses 
in their series may explain this difference. 
Oetgen et al. (12) reported a negative experience with 
four patients. In two of them, ventricular tachycardia was 
noninducible during ftecainide treatment, but one of these 
patients was later withdrawn from the study because of 
non sustained ventricular tachycardia on ambulatory electro•
cardiographic monitoring. The two initial nonresponders 
had apparent aggravation of their arrhythmia by ftecainide 
treatment. One of these two had a serum ftecainide level of 
1,402 ng/ml, which we considered to be in a toxic range. 
We experienced a low success rate in patients who were 
treated after an episode of sudden cardiac death (Group I). 
The protocol required the investigators to use ftecainide as 
a single drug for long-term treatment in these patients. Our 
low success rate may have been due in part to the unwill•
ingness of the investigators to follow the protocol in this 
group of patients unless all tachyarrhythmias were elimi•
nated in the laboratory. The five patients whose arrhythmia 
was noninducible during treatment with ftecainide had no 
recurrence of arrhythmia during long-term follow-up. How•
ever, five additional patients from Group II who were dis•
charged on ftecainide therapy despite persistent inducibility 
of a slower rhythm in the laboratory also remained free of 
clinical recurrences. Two of them received a concomitant 
beta-receptor blocking agent for other indications. Thus, it 
may be that complete elimination of ventricular tachycardia 
during electrophysiologic testing is neither a necessary nor 
the best predictive finding of long-term success of the drug. 
This delicate question was obviously not answered by our 
study. 
Adverse effects of therapy. Flecainide is well tolerated 
and none of our patients had to discontinue treatment be•
cause of intolerable subjective side effects. In this regard, 
the drug compares well with most other antiarrhythmic drugs; 
procainamide, for example, has an incidence of side effects 
ranging from 5 to 48%, and quinidine has an incidence 
ranging from 18 to 29%, as reported in a recent review (13). 
Legrand et al. (14) reported a depressant effect of ftecainide 
on left ventricular function during acute hemodynamic stud-
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ies. We encountered symptomatic worsening of left ven•
tricular function in only one patient (2.6%). 
Flecainide, like all antiarrhythmic drugs (15), may have 
proarrhythmic effects, which we observed in four patients 
(10%). One of the four who had aggravation of arrhythmia 
had a life-threatening arrhythmia, and the others had more 
frequent or incessant ventricular tachycardia that was slower 
and hemodynamically well tolerated. The left ventricular 
ejection fraction of these four patients ranged from 17 to 
35%. Trough plasma f1ecainide levels, available in two of 
these patients, were 573 and 1,054 ng/ml, respectively. This 
incidence of proarrhythmic effect is similar to that reported 
by Morganroth and Horowitz (16), who observed occur•
rence of proarrhythmic effects in 44 of 588 patients enrolled 
at various centers. It occurred in 12% of patients treated for 
symptomatic ventricular tachycardia or ventricular fibrilla•
tion and in 4% of patients treated for chronic nonsustained 
ventricular arrhythmias. They also reported a 2.8-fold in•
crease in the incidence of proarrhythmic effects in patients 
with ventricular tachycardia and congestive heart failure. 
We have not encountered any serious biochemical ab•
normalities or effects on renal, hematopoeitic or hepatic 
function in any of our patients over the follow-up period. 
Limitations of the study. To some degree, this study 
suffers from a lack of uniformity in the enforcement of its 
protocol and in the therapeutic decision making. Most in•
consistencies were inherent in the life-threatening nature of 
the condition being treated, forcing the investigators to make 
certain decisions on the basis of ethical rather than scientific 
considerations. Furthermore, the multicenter aspect of this 
trial undoubtedly accentuated the variabilities in clinical 
management. We also recognize the vagaries of interpre•
tation associated with the induction of nonsustained ven•
tricular tachycardia, and its suboptimal value as an end point 
of therapy in patients having recurrent sustained ventricular 
tachycardia or survivors of sudden cardiac death. In some 
instances, however, nonsustained ventricular tachycardia may 
be the only tachyarrhythmia induced in the laboratory that 
is both reproducible and acceptable from a practical and 
ethical standpoint. 
Conclusion. The results of this multicenter study sug•
gest that f1ecainide may be an effective agent for the long•
term treatment of recurrent sustained ventricular arrhythmias 
even when several other drugs have been unsuccessful. Its 
role as a single agent in the management of patients resus•
citated from sudden cardiac death and the value of electro•
physiologic testing in predicting its long-term effectiveness 
remain to be defined. It is usually well tolerated but can on 
occasion depress left ventricular function. In addition, 
proarrhythmic complications should be expected in at least 
10% of patients with symptomatic ventricular tachycardia 
treated with f1ecainide, and seem more likely to occur in 
the presence of left ventricular dysfunction. Thus, as with 
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all effective antiarrhythmic drugs, therapy with f1ecainide 
should be initiated under close in-hospital monitoring. 
We thank Kenneth Schechtman, PhD for performing the statistical analysis 
and Laurie A. Voigt for her diligent preparation of this manuscript. 
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